myriamed GmbH

myriamed GmbH is a biotechnology and pharmaceutical startup that focuses on accelerating drug development. With their proprietary human cell and engineered tissue organoid models, they aim to simulate health and disease in the dish. By leveraging their platform technologies, myriamed offers a broad portfolio of highly standardized services and custom-made solutions to expedite drug development, from the early stages of lead discovery to advanced individualized phenotypic screens. Founded in 2012, myriamed's primary focus is on the heart and skeletal muscle, utilizing their myrCell and myrTissue platforms to define the desired and undesired drug effects in a unique human context. Their myrScreen combines expertise in phenotypic drug screens, enabling deep phenotyping of drug effects on healthy or diseased human heart and skeletal muscle. Overall, myriamed's innovative approach to drug development presents a promising investment opportunity for those interested in the biotechnology and pharmaceutical industries.